Aug 9, 2012 by Brian Orelli, PhDA Spectrum of ValuationsSpectrum Pharmaceuticals is dirt cheap -- if it can keep sales going.
Aug 9, 2012 by Brian Orelli, PhDA Sign This Biotech Is All Grown-UpAmgen's drug fails and investors hardly flinch.
Aug 8, 2012 by Brian Orelli, PhDIt's Full Speed Ahead for This BiotechThe FDA gives ViroPharma the go-ahead on Cinryze.
Aug 8, 2012 by Brian Orelli, PhD100% Late to the PartyAchillion provides good results but needs a partner.
Aug 6, 2012 by Brian Orelli, PhD3 Drugs Approved, but Only 1 MattersRegeneron gets Zaltrap approved, Eylea still more important.
Aug 3, 2012 by Brian Orelli, PhDBiotech Investors: We Don't Do MathIncyte falls on a change in revenue recognition?
Aug 2, 2012 by Brian Orelli, PhDSafety Can't Be an AfterthoughtBristol-Myers Squibb halts dosing of its hepatitis C drug.
Aug 2, 2012 by Brian Orelli, PhDExpected Rejection, Unexpected ConsequencesHalozyme gets slammed after an FDA rejection.
Aug 1, 2012 by Brian Orelli, PhDNo Partner = Better Buyout Candidate?Idenix and Novartis restructure their deal.
Jul 31, 2012 by Brian Orelli, PhDThe Investment Lesson in Groupon Killing Small BusinessesKeep track of days sales outstanding .
Jul 31, 2012 by Brian Orelli, PhDA Non-Earnings Boost for VertexGood clinical-trial data overshadows a wimpy earnings report.
Jul 31, 2012 by Brian Orelli, PhD3 Reasons to Sell Spectrum PharmaceuticalsIt's helpful to know the bear side.
Jul 30, 2012 by Brian Orelli, PhD1 Biotech, 1 Week, 2 FDA DecisionsIt's going to be a wild week for Regeneron.
Jul 30, 2012 by Brian Orelli, PhDDepressing, in More Ways Than OneSalix and Progenics both affected by the FDA's rejection of Relistor.
Jul 27, 2012 by Brian Orelli, PhDApproved Drug for Sale at Right PriceAmarin gets approval of Vascepa and puts it on the market.
Jul 27, 2012 by Brian Orelli, PhDForget the Numbers, This Pipeline Is KingGilead's pipeline is once again an integral part of its growth story.
Jul 26, 2012 by Brian Orelli, PhDThis Biotech Keeps on WinningThe stellar launch of Regeneron's Eylea continues.
